AGÕæÈ˹ٷ½

STOCK TITAN

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Neuronetics (NASDAQ: STIM), a commercial stage medical technology company, has announced inducement awards for six new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of restricted stock units (RSUs) ranging from 1,200 to 18,750 units per employee, with specific vesting schedules over 3-4 years.

The company specializes in neuroscience treatments, notably the NeuroStar Advanced Therapy System, which has delivered over 7.4 million treatments for major depressive disorder (MDD). Through Greenbrook TMS centers, Neuronetics has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

Neuronetics (NASDAQ: STIM), un'azienda tecnologica medica in fase commerciale, ha annunciato premi di incentivo per sei nuovi dipendenti secondo la Regola NASDAQ 5635(c)(4). I premi consistono in unità azionarie vincolate (RSU) che variano da 1.200 a 18.750 unità per dipendente, con piani di maturazione specifici distribuiti su 3-4 anni.

L'azienda è specializzata in trattamenti neuroscientifici, in particolare con il NeuroStar Advanced Therapy System, che ha effettuato oltre 7,4 milioni di trattamenti per il disturbo depressivo maggiore (MDD). Attraverso i centri Greenbrook TMS, Neuronetics ha fornito più di 1,8 milioni di trattamenti a oltre 55.000 pazienti affetti da depressione.

Neuronetics (NASDAQ: STIM), una empresa de tecnología médica en etapa comercial, ha anunciado premios de incentivo para seis nuevos empleados bajo la Regla 5635(c)(4) de NASDAQ. Los premios consisten en unidades de acciones restringidas (RSU) que van desde 1,200 hasta 18,750 unidades por empleado, con calendarios de adquisición específicos de 3 a 4 años.

La compañía se especializa en tratamientos de neurociencia, especialmente con el Sistema de Terapia Avanzada NeuroStar, que ha realizado más de 7.4 millones de tratamientos para el trastorno depresivo mayor (MDD). A través de los centros Greenbrook TMS, Neuronetics ha proporcionado más de 1.8 millones de tratamientos a más de 55,000 pacientes que luchan contra la depresión.

Neuronetics (NASDAQ: STIM)ëŠ� ìƒì—… 단계 ì˜ë£Œ 기술 회사ë¡�, NASDAQ ìƒìž¥ 규칙 5635(c)(4)ì—� ë”°ë¼ 6ëª…ì˜ ì‹ ìž… ì§ì›ì—게 ì¸ì„¼í‹°ë¸Œ ìƒì„ 발표했습니다. ìƒì€ ì§ì›ë‹� 1,200ì—서 18,750 단위ì� 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ë¡� 구성ë˜ë©°, 3~4ë…„ì— ê±¸ì¹œ 특정 베스íŒ� ì¼ì •ì� ì ìš©ë©ë‹ˆë‹�.

ì� 회사ëŠ� 신경과학 치료ë¥� 전문으로 하며, 특히 NeuroStar Advanced Therapy Systemì€ ì£¼ìš” 우울 장애(MDD)ë¥� 위해 7.4백만 ê±� ì´ìƒì� 치료ë¥� 제공했습니다. Greenbrook TMS 센터ë¥� 통해 NeuroneticsëŠ� 우울ì¦ìœ¼ë¡� 고통받는 55,000ëª� ì´ìƒì� 환ìžì—게 180ë§� ê±� ì´ìƒì� 치료ë¥� 제공했습니다.

Neuronetics (NASDAQ : STIM), une entreprise technologique médicale en phase commerciale, a annoncé des récompenses d'incitation pour six nouveaux employés conformément à la règle NASDAQ 5635(c)(4). Ces récompenses comprennent des unités d'actions restreintes (RSU) allant de 1 200 à 18 750 unités par employé, avec des calendriers d'acquisition spécifiques sur 3 à 4 ans.

L'entreprise est spécialisée dans les traitements en neurosciences, notamment le Système de Thérapie Avancée NeuroStar, qui a réalisé plus de 7,4 millions de traitements pour le trouble dépressif majeur (MDD). Grâce aux centres Greenbrook TMS, Neuronetics a fourni plus de 1,8 million de traitements à plus de 55 000 patients souffrant de dépression.

Neuronetics (NASDAQ: STIM), ein medizintechnisches Unternehmen in der kommerziellen Phase, hat Anreizprämien für sechs neue Mitarbeiter gemäß NASDAQ-Listenregel 5635(c)(4) angekündigt. Die Prämien bestehen aus Restricted Stock Units (RSUs) im Bereich von 1.200 bis 18.750 Einheiten pro Mitarbeiter, mit spezifischen Vesting-Zeitplänen über 3-4 Jahre.

Das Unternehmen ist auf Neurowissenschaftsbehandlungen spezialisiert, insbesondere auf das NeuroStar Advanced Therapy System, das über 7,4 Millionen Behandlungen bei Major Depression (MDD) durchgeführt hat. Über die Greenbrook TMS-Zentren hat Neuronetics mehr als 1,8 Millionen Behandlungen für über 55.000 Patienten mit Depressionen bereitgestellt.

Positive
  • Company has treated over 55,000 patients through Greenbrook TMS centers
  • NeuroStar system has delivered 7.4 million treatments, demonstrating significant market penetration
  • Multiple FDA clearances for NeuroStar system across different indications including MDD and OCD
Negative
  • RSU grants may lead to minor shareholder dilution

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics� Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Restricted stock units (“RSUs�) 

±·²¹³¾±ðÌýNumber of Inducement Plan RSUs Vesting Schedule 
Tyler Vandermeer 1,2001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Nisha Sikarwar  1,5001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Geoff Davidson 4,5001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Jeff Gaskill 4,5001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Lola Judek 1,2001/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Jay Zubrey11,2501/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Jay Zubrey7,5001/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.


About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit .

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499

Media:
EvolveMKD
646-517-4220

____________________________
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit .


FAQ

What inducement awards did Neuronetics (STIM) announce in August 2025?

Neuronetics announced RSU grants to six new employees, with awards ranging from 1,200 to 18,750 units per employee, vesting over 3-4 years.

How many treatments has Neuronetics' NeuroStar system delivered for depression?

The NeuroStar Advanced Therapy system has delivered more than 7.4 million treatments and is backed by the largest clinical data set of any TMS treatment system for depression.

What conditions is Neuronetics' NeuroStar system FDA-cleared to treat?

NeuroStar is FDA-cleared for adults with MDD, as an adjunct for adults with OCD, for anxiety symptoms in adult MDD patients, and as a first-line adjunct for MDD in adolescents aged 15-21.

How many patients has Greenbrook TMS treated with Neuronetics' technology?

Greenbrook TMS centers have provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
Neuronetics

NASDAQ:STIM

STIM Rankings

STIM Latest News

STIM Latest SEC Filings

STIM Stock Data

300.49M
35.64M
9.48%
62.58%
7.12%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
MALVERN